• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.3 no.2
• /
• pp.72-79
• /
• 2017

Arbutin is a hydroquinone derivative with a glucose moiety. As a tyrosinase inhibitor, it is widely used as a skin-whitening cosmetic agent for the treatment of cutaneous hyperpigmentary disorders, such as melasma and freckles. In the medical field, many studies have addressed the use of arbutin in various tumors, but the mechanism for tumor uptake of arbutin is still unclear. In this paper, we radiolabeled arbutin using radioiodine and studied its pharmacokinetics and tumor uptake via biodistribution experiments and single-photon emission computed tomography (SPECT) imaging. Radiolabeled $^{131}I-arbutin$ was stable for up to 24 h in PBS and serum. Biodistribution studies and SPECT imaging indicated high uptake of the compound in the bladder and kidneys shortly after injection. Twenty-four hours post-injection, significant deiodination was observed. Apart from high thyroid uptake, selective tumor uptake was clearly observed. The tumor-to-muscle and tumor-to-blood ratios were 26 and 9, respectively.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.4 no.1
• /
• pp.3-10
• /
• 2018

The folate receptor (FR) is a promising cell membrane-associated target for nuclear imaging of various cancers (via imaging $FR-{\alpha}$) and potentially also inflammatory diseases (via imaging $FR-{\beta}$), through the use of folic acid-based radioconjugates. However, there have been several drawbacks of previously reported radioconjugates, such as a short half-life of the radiolabel ($^{68}Ga\;t_{1/2}$ 68 min), a complex and time-consuming multistep radiosynthesis, and a high renal uptake of radiolabeled folate derivatives. The goal of this study was to develop an imaging probe by directly labeling folate with radioactive iodine without using an extra prosthetic group. The radiolabeling of folate was optimized using various labeling conditions and the labeled tracers were isolated by high-performance liquid chromatography. The in vitro stability of labeled folate was checked in phosphate-buffered saline and serum. The tumor-targeting efficacy of the probe was also evaluated by biodistribution studies using a murine 4T1 tumor model.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.6 no.2
• /
• pp.146-154
• /
• 2020

Selective installation of proteins using chemical reagents is important for the development of potential biomaterials for the treatment of human diseases. However, modification in a chemo- and regioselective manner under physiological conditions is a great challenge due to the presence of multiple reactive centers in the protein. Currently, the majority of conjugations are limited to lysine (Lys)- and cysteine (Cys)-selective reagents. Thus, they have been extensively studied. Apart from Lys and Cys, widespread site selectivity has been recently achieved through most of the 20 naturally occurring amino acid-bearing reactive functional groups. Consequently, this review focused on several recent achievements in site-selective modification of the rarest amino acid backbones (e.g., methionine, serine, glutamic acid, and tyrosine).

• Molecular & Cellular Toxicology
• /
• v.3 no.3
• /
• pp.198-207
• /
• 2007

[ $^{18}F$ ]-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) scan has been found to reflect tumor aggressiveness and prognosis in various types of cancer. In this study, the gene expression profiles of glial tumors were evaluated to determine whether glial tumors with high $^{18}F$-FDG uptake have more aggressive biological potential than with low uptake. Surgical specimens were obtained from the 12 patients with glial tumors (4 males and 8 females, age range 42-68 years). The tumor samples were divided into two groups based on the $^{18}F$-FDG uptake PET scan findings: high $^{18}F$-FDG uptake (n=4) and low $^{18}F$-FDG uptake (n=8). The pathological tumor grade was closely correlated with the $^{18}F$-FDG uptake pattern: Glial tumors with high $^{18}F$-FDG uptake were pathologically Edmondson-Steiner grade III, while those with low uptake were grade II. The total RNA was extracted from the frozen tissues of all glial tumors (n=12), and adjacent non-cancerous tissue (n=3). The gene expression profiles were evaluated using cDNA microarray. The glial tumors with high $^{18}F$-FDG uptake showed increase expression of 15 genes compared to those with low uptake (P<0.005). Nine genes were down-regulated. Gene expression is closely related to cell survival, cell-to-cell adhesion or cell spreading; therefore, glial tumors with high $^{18}F$-FDG uptake appear to have more aggressive biological properties than those with low uptake.

• Molecules and Cells
• /
• v.20 no.1
• /
• pp.69-73
• /
• 2005

The flavonoid, quercetin, is a low molecular weight substance found in apple, tomato and other fruit. Besides its antioxidative effect, quercetin, like other flavonoids, has a wide range of neuropharmacological actions including analgesia, and motility, sleep, anticonvulsant, sedative and anxiolytic effects. In the present study, we investigated its effect on mouse 5-hydroxytryptamine type 3 ($5-HT_{3A}$) receptor channel activity, which is involved in pain transmission, analgesia, vomiting, and mood disorders. The $5-HT_{3A}$ receptor was expressed in Xenopus oocytes, and the current was measured with the two-electrode voltage clamp technique. In oocytes injected with $5-HT_{3A}$ receptor cRNA, quercetin inhibited the 5-HT-induced inward peak current ($I_{5-HT}$) with an $IC_{50}$ of $64.7{\pm}2.2{\mu}M$. Inhibition was competitive and voltage-independent. Point mutations of pre-transmembrane domain 1 (pre-TM1) such as R222T and R222A, but not R222D, R222E and R222K, abolished inhibition, indicating that quercetin interacts with the pre-TM1 of the $5-HT_{3A}$ receptor.

• The Journal of the Korean Society for Microbiology
• /
• v.35 no.5_6
• /
• pp.330-332
• /
• 2000

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.4
• /
• pp.2687-2688
• /
• 2013

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.18
• /
• pp.8671-8671
• /
• 2016

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.17
• /
• pp.8015-8015
• /
• 2015

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.14
• /
• pp.6175-6176
• /
• 2015